<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03589833</url>
  </required_header>
  <id_info>
    <org_study_id>YISTAR</org_study_id>
    <nct_id>NCT03589833</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA</brief_title>
  <acronym>YISTAR</acronym>
  <official_title>Effectiveness and Safety of Tumor Necrosis Factor Receptor Fusion Protein(Yisaipu) Combined With Tripterygium Wilfordii for Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this 24-week, multi-center, randomized, double-blind study, the investigators will
      evaluate the efficacy and safety profile of subcutaneously injected Yisaipu, a Tumor Necrosis
      Factor Receptor Fusion Protein, combined with oral Tripterygium Wilfordii for patients with
      active rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates the efficacy and safety of YISAIPU plus Tripterygium wilfordii (T2w) for
      the treatment of RA patients. YISAIPU is a recombinant human tumor necrosis factor receptor
      fusion protein, and tripterygium wilfordii is a chloroform/methanol extract of Tripterygium
      wilfordii Hook F.

      Objectives:

        1. To compare the efficacy of YISAIPU plus T2w versus MTX monotherapy for the treatment of
           signs and symptoms of RA.

        2. To evaluate the safety of YISAIPU plus T2w in patients with RA for 24 weeks.

      Design:

      This is a Phase 2, randomized, 24-week, double-blind, parallel group study, and 506 patients
      with active RA will be randomized in a 1:1:1:1 ratio to one of the following four parallel
      treatment arms:

        1. Methotrexate monotherapy

        2. T2w monotherapy

        3. YISAIPU plus methotrexate

        4. YISAIPU plus T2w

      Escape:

      On week 12, all participants with inadequate response, defined as a &lt;30% improvement of
      swollen and tender joint counts from baseline, will switch to YISAIPU plus T2w treatment
      throughout the study.

      Endpoints :

        1. ACR20, ACR50 and ACR70 response rates at 4, 12 and 24 weeks.

        2. DAS 28 (CRP) and DAS 28 (ESR) at 4, 12 and 24 weeks.

        3. EULAR response rates at 4, 12 and 24 weeks.

        4. Health assessment questionnaire (HAQ) at 4, 12 and 24 weeks.

        5. Patient assessment of arthritis pain at 4, 12 and 24 weeks.

        6. Patient and physician global assessment of arthritis at 4, 12 and 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">July 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The American College of Rheumatology 50 (ACR50) response at 12 weeks</measure>
    <time_frame>week 12</time_frame>
    <description>The difference of ACR50 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The American College of Rheumatology 20/70 (ACR20/ACR70) response at 12 weeks</measure>
    <time_frame>week 12</time_frame>
    <description>The difference of ACR20 and ACR70 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The American College of Rheumatology 20/50/70 (ACR20/ACR50/ACR70) response at 24 weeks</measure>
    <time_frame>week 24</time_frame>
    <description>The difference of ACR20, ACR50 and ACR70 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Disease Activity Score-28 (DAS28) response at 24 weeks</measure>
    <time_frame>week 24</time_frame>
    <description>The change in DAS28 score from baseline to week 24 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX).
DAS28 ＝ 0.56*SQRT(TJC28) + 0.28*SQRT(SJC28) + 0.36*ln(CRP + 1) + 0.014*GH + 0.96
TJC28: The number of tender joints (0-28).
SJC28: The number of swollen joints (0-28).
CRP: The C-Reactive Protein level (in mg/l).
GH: The patient global health assessment (from 0=best to 100=worst).
The 28 joint: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and the knees.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The European League Against Rheumatism (EULAR) response at 12 weeks</measure>
    <time_frame>week 12</time_frame>
    <description>The difference of proportions of patients meeting EULAR response between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX) at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire without Didability Index (HAQ-DI) at 12 weeks</measure>
    <time_frame>week 12</time_frame>
    <description>The change in HAQ-DI score from baseline to week 12 between Arm 4 (Yisaipu + Tripterygium Wilfordii) and Arm 1 (MTX).
HAQ-DI is an index measuring the quality of life related to health, which includes 20 questions in terms of three categories:
from 0 to 1: mild difficulties to moderate disability,
from 1 to 2: disability moderate to severe,
from 2 to 3: severe to very severe disability.
The mean score is recorded as the result.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">504</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>MTX</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treated with oral methotrexate and two placebos.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tripterygium Wilfordii</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treated with oral Tripterygium Wilfordii and two placebos.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yisaipu + MTX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yisaipu + Tripterygium Wilfordii</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tripterygium Wilfordii</intervention_name>
    <description>Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.</description>
    <arm_group_label>Tripterygium Wilfordii</arm_group_label>
    <arm_group_label>Yisaipu + Tripterygium Wilfordii</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.</description>
    <arm_group_label>MTX</arm_group_label>
    <arm_group_label>Yisaipu + MTX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yisaipu</intervention_name>
    <description>Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.</description>
    <arm_group_label>Yisaipu + MTX</arm_group_label>
    <arm_group_label>Yisaipu + Tripterygium Wilfordii</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years with informed consent

          -  Fulfill the 2010 ACR/EULAR classification criteria for rheumatoid arthritis

          -  Disease duration &gt; 6 weeks

          -  Swollen joint (SJC)≥4 and tender joint count(TJC)≥4

          -  ESR &gt;28 mm/hr or C-reactive protein &gt; 1.5 ULN

          -  Positive RF or anti-CCP antibody on screening

          -  Class I, II or III of the ACR 1991 Revised Criteria for Global Functional Status in RA

          -  No evidence of active or latent or inadequately treated Mycobacterium tuberculosis
             infection

        Exclusion Criteria:

          -  Pregnant, lactating or further fertility requirements

          -  Previously received any biologic agents.

          -  Recently (&lt;12 weeks) received methotrexate, leflunomide, salazosulfapyridine,
             azathioprine, cyclosporine, mycophenolate mofetil or Tripterygium Wilfordii.

          -  Active or chronic infection, including HIV, HCV, HBV, tuberculosis.

          -  History of any other rheumatic autoimmune disease

          -  History of any lymphoproliferative disorder

          -  Malignancy or history of malignancy.

          -  Abnormal laboratory tests, including: Hemoglobin &lt;8.5 g/dL, White blood cell count
             &lt;3.5 x 109/L, Platelet count &lt;100 x 109/L, AST/ALT &gt;1.5 ULN, and serum creatine &gt; 1.5
             mg/dL.

          -  Severe, progressive, or uncontrolled cardiac, pulmonary, renal, hepatic,
             gastrointestinal, hematologic, metabolic, endocrine or neurologic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuan Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Chen, MD</last_name>
    <phone>+861069158795</phone>
    <email>chenhua@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Deptment of Rheumatology, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuan Zhang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xuan Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>July 17, 2018</last_update_submitted>
  <last_update_submitted_qc>July 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Xuan Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Tripterygium</keyword>
  <keyword>TNF inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

